CHRNA3 — Cholinergic Receptor Nicotinic Alpha 3

CHRNA3 — Cholinergic Receptor Nicotinic Alpha 3

Introduction

CHRNA3 (Cholinergic Receptor Nicotinic Alpha 3) encodes the α3 subunit of the nicotinic acetylcholine receptor (nAChR) family. This subunit is primarily expressed in autonomic ganglia and plays a crucial role in peripheral cholinergic transmission, autonomic function, and cognitive processes. CHRNA3 has been associated with smoking behavior, lung cancer susceptibility, and various neurological disorders. This page covers the gene's structure, function, disease associations, and therapeutic implications for neurodegenerative diseases.

CHRNA3 — Cholinergic Receptor Nicotinic Alpha 3

Introduction

CHRNA3 (Cholinergic Receptor Nicotinic Alpha 3) encodes the α3 subunit of the nicotinic acetylcholine receptor (nAChR) family. This subunit is primarily expressed in autonomic ganglia and plays a crucial role in peripheral cholinergic transmission, autonomic function, and cognitive processes. CHRNA3 has been associated with smoking behavior, lung cancer susceptibility, and various neurological disorders. This page covers the gene's structure, function, disease associations, and therapeutic implications for neurodegenerative diseases.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cholinergic Receptor Nicotinic Alpha 3</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>CHRNA3</td></tr>
<tr><td><strong>Full Name</strong></td><td>Cholinergic receptor nicotinic alpha 3 subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>15q25.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[1136](https://www.ncbi.nlm.nih.gov/gene/1136)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[118505](https://www.omim.org/entry/118505)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000138028</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P30531](https://www.uniprot.org/uniprotkb/P30531)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Lung cancer](/diseases/lung-cancer), [Cognitive impairment](/diseases/cognitive-impairment), [Autonomic dysfunction](/diseases/autonomic-dysfunction), [Alzheimer's Disease](/diseases/alzheimers-disease)</td></tr>
</table>
</div>

Overview

CHRNA3 is a member of the Cys-loop receptor superfamily, similar to CHRNA2, but with distinct expression patterns and physiological roles. The α3 subunit primarily forms heteromeric nAChRs in the peripheral nervous system, particularly in autonomic ganglia where it mediates fast cholinergic synaptic transmission between preganglionic and postganglionic neurons.

Key characteristics:

• Primary expression in autonomic (parasympathetic and sympathetic) ganglia
• Forms functional receptors with β2, β4, and sometimes α5 subunits
• Mediates ganglionic neurotransmission
• Genetic variants associated with smoking behavior and lung cancer risk

Protein Structure

Overall Architecture

CHRNA3 shares the general architecture of Cys-loop receptors:

• Extracellular N-terminal domain: ACh binding site
• Transmembrane domain: Four α-helices (M1-M4)
• Intracellular loop: Between M3 and M4
• Extracellular C-terminal domain

Acetylcholine Binding Site

The ACh binding site in α3-containing receptors:

• Located at α3:β subunit interfaces
• Conserved aromatic residues for ACh coordination
• C-loop provides conformational changes upon binding

Structural Features

| Feature | Description |
|---------|-------------|
| Signal peptide | 23-25 amino acid N-terminal leader |
| N-terminal extracellular | ~210 aa with 5 conserved cysteines |
| Cys-loop | Characteristic C-terminus of extracellular domain |
| M1-M4 helices | 4 transmembrane domains |
| C-terminal intracellular | Variable length (30-80 aa) |

Receptor Subtypes

CHRNA3 forms several receptor combinations:

| Receptor | Stoichiometry | Location | Function |
|----------|---------------|----------|----------|
| α3β2 | α3:β2 = 2:3 | CNS, autonomic | Synaptic transmission |
| α3β4 | α3:β4 = 2:3 | Autonomic ganglia | Major ganglionic receptor |
| α3α5β2 | α3:α5:β2 = 1:1:3 | CNS | Higher Ca²⁺ permeability |
| α3α5β4 | α3:α5:β4 = 1:1:3 | Autonomic | Enhanced function |

The inclusion of α5 increases Ca²⁺ permeability and is associated with nicotine dependence.

Expression Pattern

Peripheral Nervous System

• Autonomic ganglia: Superior cervical ganglion, stellate ganglion, pelvic ganglia
• Enteric nervous system: Myenteric and submucosal plexus
• Adrenal medulla: Chromaffin cells

Central Nervous System

• Thalamus: Relay neurons
• Hippocampus: Interneurons
• Cortex: Layer 2/3 neurons
• Brainstem: Autonomic nuclei

Non-Neuronal

• Lung: Epithelial cells (15q25.1 cluster with CHRNA5)
• Immune cells: T-lymphocytes, macrophages

Role in Autonomic Function

Ganglionic Transmission

CHRNA3 is the primary mediator of fast cholinergic transmission in autonomic ganglia:

Autonomic Control

α3-containing receptors regulate:

• Sympathetic: Heart rate, vasoconstriction, pupil dilation
• Parasympathetic: Salivation, GI motility, bronchoconstriction
• Enteric: GI secretion, peristalsis

Autonomic Dysfunction

Impaired α3 function contributes to:

• Orthostatic hypotension
• Gastrointestinal dysmotility
• Urinary retention
• Sexual dysfunction

Role in Alzheimer's Disease

Cholinergic Deficiency

AD is characterized by progressive cholinergic neuron loss:

• Basal forebrain cholinergic neurons degenerate
• Decreased acetylcholine in cortex and hippocampus
• nAChR expression is altered

α3-Containing Receptors in AD

• CHRNA3 expression is reduced in AD brains
• α3* nAChRs modulate hippocampal synaptic function
• Nicotinic agonists may provide symptomatic benefit

Therapeutic Potential

• Partial nAChR agonists (e.g., varenicline) tested in AD
• α3-selective compounds may reduce side effects
• Combination with AChE inhibitors (donepezil, rivastigmine)

Genetic Associations

CHRNA3/CHRNA5 Cluster

The 15q25.1 locus contains a cluster of nAChR subunit genes:

• CHRNA3
• CHRNA5
• CHRNB4

Smoking Behavior

• rs16969968 (CHRNA5, Asn398Asp) is strongest predictor
• rs578776 (CHRNA3) also associated
• Contributes to nicotine dependence and smoking initiation

Lung Cancer Risk

• 15q25.1 variants associated with lung cancer risk
• May be partially mediated through smoking behavior
• Independent effect on lung cancer susceptibility also reported

Neurological Disorders

• Association with cognitive function in elderly
• Potential role in AD and PD risk
• Epilepsy: rare CHRNA3 mutations

Disease Associations

| Disease | Association | Mechanism |
|---------|-------------|-----------|
| Lung Cancer | Strong (rs16969968, rs578776) | Smoking behavior + direct effect |
| Cognitive Impairment | Moderate | nAChR signaling in cognition |
| Autonomic Dysfunction | Moderate | Ganglionic transmission |
| Alzheimer's Disease | Potential | Cholinergic signaling deficit |
| Epilepsy | Rare variants | Channel dysfunction |

Therapeutic Implications

Nicotinic Agonists

Applications

• Smoking cessation (primary use for α4β2, also α3β4)
• Autonomic dysfunction (if selective agonists available)
• Cognitive enhancement in AD (broader nAChR targeting)

Challenges

• Autonomic side effects (tachycardia, hypertension)
• Nicotine tolerance and dependence
• Lack of truly selective compounds

Key Publications

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Autonomic Dysfunction](/diseases/autonomic-dysfunction)
• [Acetylcholine Signaling](/mechanisms/acetylcholine-signaling)
• [Nicotinic Receptors](/mechanisms/nicotinic-receptor-signaling)
• [Cholinergic System](/mechanisms/cholinergic-system)
• [Autonomic Nervous System](/mechanisms/autonomic-nervous-system)
• [Synaptic Transmission](/mechanisms/synaptic-transmission)

References